Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Watch an on-demand webcast and download slides from a live symposium covering the latest on HER3- and TROP2-targeted antibody‒drug conjugates for NSCLC, breast cancer, and other solid tumors.

Share

Program Content

Activities

HER3 ADCs
HER3 as a Target for ADCs: Rationale and Clinical Evidence
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 19, 2023

ADC Overview
An Overview of ADCs: Key Structural Features and Potential Adverse Events
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 20, 2023

TROP2 ADCs
Evolution of TROP2-Targeted ADCs in Solid Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 20, 2023

Activities

TROP2 and HER3 ADCs
Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2023

Expires: May 22, 2024

Faculty

cover img faculity

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.